Abstract #1177

Cervical cancer staging and surveillance using Restriction Spectrum Imaging (RSI)-MRI in comparison to PET-CT: Pilot Clinical Application

Ghiam Yamin¹, Kaveh Zakeri², Natalie M. Schenker-Ahmed¹, Nathan S. White¹, Hauke Bartsch¹, Joshua Kuperman¹, Loren K. Mell², Michael Hahn¹, David S. Karow¹, Anders M. Dale³, and Rebecca A. Rakow-Penner¹

¹Radiology, University of California, San Diego, San Diego, CA, United States, ²Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, CA, United States, ³Radiology & Neurosciences, University of California, San Diego, La Jolla, CA, United States

This proof of concept study suggests restriction spectrum imaging (RSI)-magnetic resonance imaging (MRI) provides similar cervical cancer staging and surveillance information compared to standard of care MP-MRI and PET-CT. Advantages over the standard of care modalities may include improved cost-effectiveness, brevity, radiation-free, and contrast media-free. Pilot cases suggest that RSI-MRI cellularity index can detect residual and recurrent tumor in post-treatment cervical cancer patients with similar sensitivity to PET-CT. RSI-MRI has the advantage of minimal false positive results related to radiation-related post-treatment changes that often confound interpretation of PET-CT.

This abstract and the presentation materials are available to members only; a login is required.

Join Here